Precigen (NASDAQ:PGEN - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.
A number of other equities research analysts have also recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Precigen in a research note on Thursday, March 20th. JMP Securities reissued a "market outperform" rating and set a $6.00 target price on shares of Precigen in a research note on Thursday, June 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Precigen in a research note on Thursday, May 15th.
Get Our Latest Report on Precigen
Precigen Stock Performance
Shares of NASDAQ PGEN traded down $0.08 during trading on Friday, reaching $1.83. The stock had a trading volume of 1,347,585 shares, compared to its average volume of 1,465,889. Precigen has a fifty-two week low of $0.65 and a fifty-two week high of $2.17. The business's 50-day moving average price is $1.46 and its 200-day moving average price is $1.48. The company has a market cap of $540.18 million, a P/E ratio of -3.27 and a beta of 1.78.
Precigen (NASDAQ:PGEN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Precigen had a negative return on equity of 279.20% and a negative net margin of 3,728.87%. The business had revenue of $1.34 million during the quarter, compared to analysts' expectations of $0.50 million. Analysts forecast that Precigen will post -0.32 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Voya Investment Management LLC lifted its holdings in Precigen by 142.9% during the 1st quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock worth $55,000 after buying an additional 21,633 shares during the last quarter. Inspire Investing LLC purchased a new stake in Precigen during the 1st quarter worth about $350,000. Strs Ohio purchased a new stake in Precigen during the 1st quarter worth about $70,000. Parkman Healthcare Partners LLC purchased a new stake in Precigen during the 1st quarter worth about $4,755,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Precigen by 12.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company's stock worth $122,000 after buying an additional 9,043 shares during the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.
Precigen Company Profile
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Featured Articles
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
